Trials / Not Yet Recruiting
Not Yet RecruitingNCT06512363
A Study of Ramelteon in Chinese Patients With Chronic Insomnia
A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Ramelteon in Chinese Patients With Chronic Insomnia
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia. Efficacy will be evaluated on objective and subjective sleep parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramelteon | Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks. |
| DRUG | Ramelteon placebo | Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks. |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-07-22
- Last updated
- 2024-07-22
Source: ClinicalTrials.gov record NCT06512363. Inclusion in this directory is not an endorsement.